| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PATH.2048 |
| P698 | PubMed publication ID | 16917801 |
| P50 | author | Marco Matucci-Cerinic | Q19859583 |
| Stefano Bombardieri | Q73477457 | ||
| P2093 | author name string | Del Rosso A | |
| Guiducci S | |||
| Pucci M | |||
| Margheri F | |||
| Del Rosso M | |||
| Cinelli M | |||
| Fibbi G | |||
| Serratì S | |||
| Bazzichi L | |||
| P2860 | cites work | Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs | Q38356033 |
| Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549 | Q41311259 | ||
| P433 | issue | 2 | |
| P921 | main subject | endothelium | Q111140 |
| P304 | page(s) | 240-248 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | Journal of Pathology | Q400296 |
| P1476 | title | Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor. | |
| P478 | volume | 210 |
| Q40955749 | Aging is protective against pressure overload cardiomyopathy via adaptive extracellular matrix remodeling |
| Q37956146 | Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts |
| Q38771824 | Biomarkers in Scleroderma: Progressing from Association to Clinical Utility |
| Q37768336 | Cellular and molecular aspects of vascular dysfunction in systemic sclerosis |
| Q38156227 | Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development |
| Q34924478 | Density enhanced phosphatase-1 down-regulates urokinase receptor surface expression in confluent endothelial cells |
| Q39883132 | Early matrix metalloproteinase-12 inhibition worsens post-myocardial infarction cardiac dysfunction by delaying inflammation resolution |
| Q58770056 | Integration of Genome-Wide DNA Methylation and Transcription Uncovered Aberrant Methylation-Regulated Genes and Pathways in the Peripheral Blood Mononuclear Cells of Systemic Sclerosis |
| Q35832033 | Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo |
| Q38729906 | Matrix Metalloproteinases in Myocardial Infarction and Heart Failure. |
| Q58575591 | Matrix metalloproteinase-12 as an endogenous resolution promoting factor following myocardial infarction |
| Q38024303 | Matrix metalloproteinases: a review of their structure and role in systemic sclerosis |
| Q36960275 | Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling |
| Q37310583 | Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis |
| Q38905882 | Microfluidic multiculture assay to analyze biomolecular signaling in angiogenesis |
| Q41976893 | Shedding of NG2 by MMP-13 attenuates anoikis |
| Q45304157 | Systemic sclerosis endothelial cells recruit and activate dermal fibroblasts by induction of a connective tissue growth factor (CCN2)/transforming growth factor β-dependent mesenchymal-to-mesenchymal transition |
| Q85188343 | The Plasminogen Activator System in Fibroblasts from Systemic Sclerosis |
| Q64277722 | The Role of Fibrinolytic Regulators in Vascular Dysfunction of Systemic Sclerosis |
| Q26995542 | Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment |
| Q42075625 | α2AP regulates vascular alteration by inhibiting VEGF signaling in systemic sclerosis: the roles of α2AP in vascular dysfunction in systemic sclerosis |
Search more.